Skip to main content
TipRanks
Go Ultimate75% OFF

NRX Pharmaceuticals (B1Q) Q2 2026 Earnings Report

1 Followers

DE:B1Q Q2 2026 EPS Results

Actual EPS
-EUR 0.40
Consensus EPS
-EUR 0.10
Beat/Miss
Missed by -EUR 0.30
One Year Ago EPS
-EUR 0.89

DE:B1Q Q2 2026 Revenue Results

Actual Revenue
EUR 998.88K
Expected Revenue
EUR 1.21M
Beat/Miss
Missed by -EUR 207.76K
YoY Revenue Growth
―

Earnings Announcement Details

Quarter
Q2 2026
Date
08/17/2026
Time
Before Open
Conference Call
Monday, August 17, 2026
DE:B1Q Upcoming Earnings

NRX Pharmaceuticals's next earnings date is estimated for November 17, 2026, based on past reporting schedules.

Q2 2026 Earnings Call Audio

DE:B1Q Q2 2026 Earnings Call
0:00 / 0:00

Q2 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q2 2026 Earnings Call Summary

Q2 2026
Earnings Call Date:Aug 17, 2026|% Change Since:-29.67%|
Earnings Call Sentiment|Positive

The call conveyed significant strategic and technical progress across multiple fronts: near-term commercialization steps (ANDA and launch-stock orders), a strengthened balance sheet (cash up ~242%), a materially expanded development pipeline via the GeNeuro acquisition, and a high-impact DARPA/military partnership with a 400-patient SPARC-TMS trial. These positives are tempered by ongoing net operating losses (operating loss up ~48.7%), regulatory/contracting uncertainties, dependence on nondilutive government funding, and the need for further financing or successful commercial milestones beyond the ~1-year cash runway. Overall, the tone is cautiously optimistic: strong strategic wins and funding momentum outweigh current financial and execution risks, but key approvals, contracts and trial execution remain critical near-term milestones.

Company Guidance

Management guided that the preservative‑free ketamine ANDA is targeted for 2026 approval after completing the first review cycle with a single remaining major deficiency (FDA requested manufacturer attestation that the vial Luer‑lock is used in products shipping >12 million units/year), 5 million units of launch stock have been ordered and the ketamine market is estimated at ~$750M; the NRX‑100 NDA is being advanced with a 2027 approval goal (PDUFA fee ~ $5M) supported by real‑world evidence from ~65,000 Americans; the DARPA‑backed SPARC‑TMS Phase II/III trial (NRx as prime contractor) is planned to enroll ~400 patients (240 at HOPE/Harvard‑McLean and 160 at military treatment facilities) and could expand NRX‑101’s addressable market to >15 million treatment‑resistant depression patients; GeNeuro’s GNK‑301 first‑in‑human is targeted for July 2027 with initial congressional/DoD funding efforts (first $3M CDMRP submission and ~$80M added to the 2027 Defense appropriation) under way; and financially NRx reported $26.7M cash as of June 30, 2026 (vs $7.8M at Dec 31, 2025), raised >$22M gross in its recent public offering, posted a 6‑month net loss of $18M (vs $23.1M prior year) and a net operating loss of $11.3M (vs $7.6M), and believes current resources plus its ATM facility will support operations for at least one year.

  • ANDA for Preservative-Free Ketamine Nearing ApprovalSingle major deficiency (Luer lock attestation) addressed and attestation submitted to FDA; company aiming for 2026 approval and has ordered 5 million units of launch stock.
  • Progress Toward NRX-100 NDAAdvancing NDA for NRX-100 to treat depression with guidance from a presidential executive order and congressional budget language supporting use of real-world evidence; company targeting 2027 approval.
  • DARPA-Funded SPARC-TMS Trial and Military PartnershipSelected as prime contractor for an FDA-approved Phase II/III SPARC-TMS trial combining NRX-101 with robotic TMS; trial expected to enroll ~400 patients (240 in HOPE/Harvard sites + 160 in military treatment facilities) with funding routed through the military (contracting ongoing).
  • Material Expansion of NRX-101 Market OpportunityNRX-101 being evaluated beyond suicidal bipolar depression for treatment-resistant depression with an addressable U.S. market of >15 million patients; potential to restore deployability/readiness for military and first responders.
  • Acquisition of GeNeuro PortfolioAcquisition finalized in June (Swiss courts) adding two clinical-stage monoclonal antibodies: GNK-301 (targeting HERV-K for ALS) and temelimab (MS, type 1 diabetes, potential schizophrenia application), creating a transformative longer-term pipeline.
  • Forward-Funded ALS Program and Near-Term MilestonesGNK-301 selected in first round of congressionally-directed medical research program for drug development/biomarker funding; first-in-human GNK-301 trial targeted for July 2027; additional defense appropriations and CDMRP opportunities identified (applied for initial $3M).
  • Stronger Cash Position and Capital RaiseCash and cash equivalents of $26.7M as of June 30, 2026 versus $7.8M at 12/31/2025 — an increase of ~242.3% — primarily from a public offering with gross proceeds >$22M; management expects current resources plus ATMs to support operations for at least one year.
  • HOPE Therapeutics Clinic Footprint ExpansionExpanded HOPE Therapeutics network to 5 clinical locations in Florida, providing a platform to deploy neuronavigation, robotic TMS and neuroplastic-assisted care and to support clinical trials (e.g., SPARC-TMS).

DE:B1Q Earnings History

DE:B1Q earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Nov 17, 20262026 (Q3)-0.19--0.24――
Aug 17, 20262026 (Q2)-0.10-0.40-0.8955.10% (+0.49)
May 18, 20262026 (Q1)0.19-0.04-0.3188.24% (+0.27)
Mar 24, 20262025 (Q4)0.010.01-0.66101.38% (+0.67)
Nov 17, 20252025 (Q3)-0.02-0.24-0.14-80.00% (-0.11)
Aug 18, 20252025 (Q2)-0.14-0.89-0.68-30.67% (-0.21)
May 15, 20252025 (Q1)-0.26-0.31-0.6754.05% (+0.36)
Mar 17, 20252024 (Q4)-0.33-0.66-0.45-44.80% (-0.20)
Nov 14, 20242024 (Q3)-0.50-0.14-0.6478.57% (+0.50)
Aug 13, 20242024 (Q2)-0.63-0.68-1.0937.50% (+0.41)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed